Sight Sciences, Inc. — Q2 2022 Form 10-Q
Business context and period: Unaudited results for the quarter and six months ended June 30, 2022. Sight Sciences develops and sells ophthalmic devices. Its Surgical Glaucoma segment sells the OMNI Surgical System; its Dry Eye segment sells the TearCare System. Nearly all revenue was generated in the United States.
Financial performance
| Metric | Q2 2022 | Q2 2021 | First half 2022 | First half 2021 |
|---|---|---|---|---|
| Revenue | $17.2m | $12.5m | $32.1m | $21.2m |
| Gross profit / margin | $14.5m / 84.1% | $10.2m / 81.6% | $26.3m / 82.0% | $16.6m / 78.2% |
| Operating expenses | $37.4m | $21.3m | $71.4m | $39.3m |
| Operating loss | $(22.9)m | $(11.1)m | $(45.1)m | $(22.7)m |
| Net loss | $(23.8)m | $(17.6)m | $(47.1)m | $(29.9)m |
| Net loss per share | $(0.50) | $(1.83) | $(0.99) | $(3.12) |
- Q2 revenue grew 37.4% year over year; first-half revenue grew 51.7%. OMNI revenue was $15.9m in Q2 and $29.8m in the first half; TearCare revenue was $1.3m and $2.3m, respectively.
- Q2 Surgical Glaucoma gross margin was 87.7%, versus 85.2% a year earlier. Dry Eye margin improved to 40.8% from 2.7%. For the first half, however, Dry Eye margin fell to 0.6% from 6.5%, reflecting, in part, $0.9m of charges related to the voluntary SmartHub 1.0 recall.
- Operating expenses rose substantially: Q2 R&D increased 67.1% and SG&A 77.0% year over year. Management attributed much of the increase to headcount and related personnel costs, including stock-based compensation, alongside higher clinical, marketing and professional-services costs.
- First-half operating cash use was $40.3m, compared with $25.3m a year earlier. Capital expenditures were $0.6m; financing provided $0.3m, primarily from stock-option exercises. Cash and cash equivalents decreased $40.6m during the half.
Financial position and liquidity
- At June 30, 2022, cash and cash equivalents were $220.1m, including $174.7m of short-term U.S. Treasury bills. Total assets were $240.7m; stockholders’ equity was $191.8m; accumulated deficit was $200.1m.
- Debt principal was $35.0m ($33.0m carrying value after unamortized discount and issuance costs). The $5.0m revolving facility was undrawn. Debt is secured by substantially all company assets, including material intellectual property; the term loan carries a floating rate of reserve-adjusted LIBOR plus 7.00%. Principal payments are scheduled to begin in December 2022, subject to conditions that may defer them.
- The company reported compliance with debt covenants and said available liquidity was expected to fund operations for at least 12 months. It also cautioned that continuing losses or insufficient revenue, margins, or cost control could require additional financing.
Outlook, risks and notable items
- No quantified revenue, earnings, or margin guidance is provided. Management expects net losses for at least the next several fiscal years and plans continued spending on clinical studies, sales and marketing, market access, and product development.
- Management said OMNI growth reflected more ordering facilities and greater utilization per facility. Lower-cost, higher-volume offshore manufacturing contributed to Surgical Glaucoma margin improvement; the company was supplementing that capacity with a U.S. manufacturer. Management expects Dry Eye margins to remain below Surgical Glaucoma margins in the near to medium term.
- COVID-19 may continue to affect elective-procedure demand and could disrupt suppliers, sales, clinical studies, or manufacturing. TearCare generally lacks meaningful Medicare or private-payor reimbursement, with patients typically paying out of pocket.
- In July 2022, the company initiated a cost-efficiency plan that included a workforce reduction completed in Q3; it expected approximately $1.0m in severance and related expenses.
- The company’s patent suit concerning the Hydrus Microstent was expanded on August 1, 2022 to name Alcon entities and add another patent. Defendants had asserted counterclaims challenging infringement and patent validity. No trial date was set, and the company said it could not predict the outcome or estimate any financial impact.
- Management concluded disclosure controls and procedures were not effective at quarter-end because of previously reported material weaknesses in financial reporting controls, including insufficient experienced accounting personnel and inadequate segregation of duties. Remediation was underway but not yet validated over sustained reporting cycles.
Important facts for investors to verify
- Whether OMNI’s revenue growth and manufacturing-related margin gains persist, and whether Dry Eye economics recover after the SmartHub recall charges.
- The pace of cash burn relative to the stated minimum 12-month liquidity outlook and the timing or conditions for term-loan principal payments.
- The continuing effects of the SmartHub 1.0 recall, including any additional costs, customer effects, or regulatory developments; the filing text does not provide a clear estimate of any further impact.
- Developments in the patent litigation, including the added defendants and patent, and any eventual financial or operational consequences.
- Progress in remediating the material weaknesses and the impact of the Q3 workforce reduction on costs and execution.